证券代码：688075 证券简称：安旭生物 公告编号：2025-024 杭州安旭生物科技股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》等相关业务 规则的规定，杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"） 董事会编制了《关于 2025 年半年度募集资金存放与实际使用情况的专项报告》。 具体如下： 截至 2025 年 6 月 30 日，公司募集资金余额为 27,585,733.85 元，具体情况如下： 单位：人民币元 | 项目 | 金额 | | | --- | --- | --- | | 募集资金净额 | | 1,055,846,296.20 | 1 | 减：直接投入募投项目 | 578,396,111.43 | | --- | --- | | 募投项目结项补充流动资金 | 47,100,230 ...

杭州安旭生物科技股份有限公司 关于公司 2025 年度提质增效重回报专项行动方案的 半年度评估报告 杭州安旭生物科技股份有限公司（以下简称"安旭生物、公司"）为提高上 市公司质量，增强投资者回报，提升投资者的获得感，维护公司全体股东利益， 基于对公司未来发展前景的信心以及对公司价值的认可，公司于 2025 年 4 月 30 日发布了《关于 2025 年度"提质增效重回报"行动方案的公告》。公司根据行 动方案内容，积极开展和落实各项工作，现将 2025 年上半年的主要工作成果报 告如下： 一、 聚焦主营业务，提升科技创新能力 公司是一家专注于 POCT 试剂及仪器的研发、生产与销售的高科技企业。公 司拥有生物原料、免疫层析、干式生化、化学发光、精准检测、液态生物芯片、 微流控、临床检验仪器等几大技术平台。发展形成了覆盖毒品检测、传染病检测、 慢性病检测、妊娠检测、肿瘤检测、心肌检测、生化检测、过敏原检测八大领域 的 POCT 试剂，已形成原料、试剂、仪器三位一体的产业链布局。产品畅销欧美、 澳洲、亚洲等 150 多个国家和地区。现已成为国内少数几家在 POCT 国际市场能 够与跨国体外诊断行业巨头竞争的中国体外 ...

智通财经APP讯，安旭生物(688075.SH)发布2025年半年度报告，报告期内，公司实现营业收入2.3亿 元，同比下降7.42%。实现归属于上市公司股东的净利润5930.59万元，同比下降48.57%。实现归属于上 市公司股东的扣除非经常性损益的净利润2358.62万元，同比增长24.85%。基本每股收益0.47元。 ...

安旭生物(688075.SH)披露2025年半年报，公司上半年实现营业收入2.3亿元，同比下降7.42%；归母净 利润为5930.59万元，同比下降48.57%。基本每股收益0.47元。报告期内，归属于上市公司股东净利润 较上年同期下降，主要系本年汇率波动引起的汇兑损失及政府补助减少。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

格隆汇8月19日丨安旭生物(688075.SH)公布2025年半年度报告，上半年实现营业收入2.3亿元，同比下降 7.42%；归属于上市公司股东的净利润5930.59万元，同比下降48.57%；归属于上市公司股东的扣除非经 常性损益的净利润2358.62万元，同比增长24.85%；基本每股收益0.47元。 ...

人民财讯8月19日电，安旭生物(688075)8月19日晚间披露2025年半年报，公司上半年实现营业收入2.3亿 元，同比下降7.42%；归母净利润为5930.59万元，同比下降48.57%。基本每股收益0.47元。报告期内， 归属于上市公司股东净利润较上年同期下降，主要系本年汇率波动引起的汇兑损失及政府补助减少。 ...

Core Viewpoint - The company is holding its first extraordinary general meeting of shareholders in 2025 to discuss several key proposals, including the cancellation of the supervisory board, cash management using idle funds, and the election of a new board of directors [1][7][9]. Group 1: Meeting Proposals - Proposal 1 involves the cancellation of the supervisory board and amendments to the company's articles of association, with the supervisory board's powers being transferred to the audit committee of the board of directors [7][8]. - Proposal 2 seeks approval to use up to RMB 4 billion of temporarily idle funds for cash management, focusing on safe and liquid investment products [8][9]. - Proposal 3 is for the election of three non-independent directors to the third board of directors, with candidates nominated for the positions [9][10]. - Proposal 4 involves the election of three independent directors to the third board of directors, with candidates also nominated for these positions [11][12]. Group 2: Meeting Procedures - The meeting will be conducted with both on-site and online voting, with specific time slots for voting outlined [4][5]. - Shareholders must register and provide identification to participate, and only registered attendees can vote on-site [2][3]. - The meeting will follow a structured agenda, including the introduction of attendees, discussion of proposals, and voting [6][8].

杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 杭 州 安 旭 生 物 科 技 股 份 有 限 公 司 2025 年第一次临时股东大会会议资料 股票简称：安旭生物 股票代码：688075 2025 年 8 月 22 日 1 杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 年第一次临时股东大会须知………………………………………………………..………3 | | --- | | 年第一次临时股东大会议程…………………………………………………………..… 5 2025 | | 议案一：关于取消监事会、修订<公司章程>并办理工商变更登记及修订相关制度的议案…7 | | 议案二：关于使用部分暂时闲置自有资金进行现金管理的议案………………………….…..8 | | 议案三：关于董事会换届选举暨选举第三届董事会非独立董事的议案………………………9 | | 议案四：关于董事会换届选举暨选举第三届董事会独立董事的议案………………….….…10 | 2 杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会须知 为了维护 ...

Group 1 - The core viewpoint is that the A-share market is stabilizing, and growth stocks are expected to rebound, with a focus on sectors less affected by external factors and more aligned with internal growth, particularly in the large financial sector [1][4]. Group 2 - The electronic industry is the most favored by brokerages, covering 127 stocks, followed closely by the pharmaceutical and mechanical equipment industries, with 125 and 124 stocks respectively [2]. - Brokerages have conducted research on 1,061 stocks this year, significantly higher than the 740 stocks researched in the same period last year [2]. - The top three brokerages in terms of research frequency are CITIC Securities, CICC, and CITIC Jiantou, with 386, 373, and 323 research instances respectively [3]. Group 3 - Brokerages are optimistic about the A-share market's future, with expectations of a recovery driven by strong performance in growth stocks, particularly in sectors like photovoltaics, wind power, smart driving, and digital economy [4]. - There are indications of multiple bottom signals in the A-share market, suggesting a potential new upward cycle as external negative factors ease [4]. - The valuation of A-shares is nearing historical lows, indicating that market rebounds are likely to continue, with a focus on previously oversold stocks and growth sectors like new energy and semiconductors [4].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anxu Biological, which closed at 42.93 yuan with a PE ratio of 34.94 times, below the industry average of 56.56 times [1][2] - Anxu Biological's total market capitalization is 5.456 billion yuan, ranking 68th in the medical device industry based on PE ratio [1][2] - The company specializes in the research, production, and sales of POCT reagents and instruments, and has received multiple certifications including EU CE, Canadian, and Australian certifications [1] Group 2 - As of March 31, 2025, Anxu Biological had 5,935 shareholders, a decrease of 278 from the previous period, with an average holding value of 352,800 yuan per shareholder [1] - The latest quarterly report for Q1 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]